Cannabis Therapy for Pain, Anxiety, and Chronic Illness

Cannabis therapy refers to the medical use of cannabis-derived compounds to treat specific symptoms or conditions, and the evidence behind it is far more uneven than either advocates or critics tend to acknowledge. A few applications have strong clinical trial support, most notably pharmaceutical-grade CBD for certain childhood epilepsy syndromes and THC-CBD sprays for multiple sclerosis spasticity. Many other uses, from chronic pain to anxiety to sleep, sit in a gray zone of promising but limited data. Understanding where the science is firm, where it is thin, and where cannabis can actually cause harm matters for anyone considering it as a treatment option.

How Cannabis Interacts With Your Body

Your body already produces its own cannabis-like molecules. The endocannabinoid system is a signaling network involved in maintaining balance across metabolism, immune response, pain processing, and brain protection. Its two main natural compounds, anandamide and 2-AG, act on receptors called CB1 and CB2, which are found throughout the brain, gut, immune cells, and other tissues.¹ When you take cannabis-derived compounds, they tap into this existing system, which is why their effects are so wide-ranging and why the same substance can influence pain, mood, appetite, and sleep simultaneously.

The two compounds that matter most therapeutically are THC and CBD. They come from the same plant and have similar chemical structures, but they behave very differently in the brain.² THC binds directly to CB1 receptors and produces the intoxicating “high” along with pain relief, appetite stimulation, and sedation. CBD does not produce a high and works through more indirect routes, influencing inflammation, serotonin signaling, and other pathways. This distinction shapes virtually every therapeutic conversation about cannabis, because the ratio of THC to CBD in a given product determines both its benefits and its side effects.

The Entourage Effect

Cannabis contains hundreds of compounds beyond THC and CBD, including terpenes, the aromatic molecules that give different strains their distinctive smells. Some researchers argue that these terpenes work together with cannabinoids to enhance therapeutic effects, a concept called the “entourage effect.”³ The idea is that a whole-plant preparation might work better for mood and anxiety than an isolated cannabinoid. This concept is genuinely interesting but remains more theoretical than proven. It comes up constantly in dispensary marketing, and you should know that rigorous clinical trials comparing whole-plant extracts to isolated compounds for the same condition are still scarce. The entourage effect is plausible, not established.

Where the Evidence Is Strongest

Epilepsy

The most convincing clinical data for cannabis therapy involves pharmaceutical-grade CBD (sold as Epidiolex) for treatment-resistant epilepsy. In a landmark trial published in the New England Journal of Medicine, patients with Lennox-Gastaut syndrome receiving 20 mg/kg of CBD daily saw a roughly 42% reduction in drop seizures, compared to about 17% with placebo.⁴ These are patients whose seizures had not responded adequately to other medications.

Longer-term data from an expanded access program showed that CBD reduced major motor seizures by half at 12 weeks, and those reductions held through 96 weeks of follow-up. About half of patients achieved at least a 50% reduction in major seizures, and a small percentage became seizure-free.⁵ Results in Dravet syndrome, another severe childhood epilepsy, followed a similar pattern, with about 30% of patients achieving a 50% seizure reduction at three months.⁶ This is the area where cannabis therapy has cleared the highest regulatory bars, with FDA approval based on multiple randomized controlled trials.

Multiple Sclerosis Spasticity

Nabiximols (brand name Sativex), an oromucosal spray containing THC and CBD in a 1:1 ratio, is approved in several countries as an add-on treatment for MS-related spasticity and neuropathic pain.⁷ Trials have shown it reduces spasticity, pain, muscle spasms, and sleep disturbances. A review of the broader evidence found that the spray improved spasticity and quality of life with tolerable side effects, while oral cannabinoids also helped with MS-related pain and spasticity.⁸

One concern with any long-term medication is whether it stops working over time. A long-term open-label study of Sativex found no evidence of tolerance developing. Patients who stayed on the medication reported continued benefit, baseline symptoms did not worsen, and no new safety problems emerged with chronic use.⁹

Chronic Pain

Pain is the most common reason people seek cannabis therapy, and the evidence here is real but modest. A Cochrane review of cannabis-based medicines for chronic neuropathic pain found that about 39% of patients taking cannabinoids achieved at least a 30% pain reduction, compared to 33% on placebo. For the higher bar of 50% pain relief, the numbers were closer together: roughly 21% with cannabis versus 17% with placebo.¹⁰ Those margins are small. The review also noted that more patients dropped out due to side effects in the cannabis group (about 10%) than in the placebo group (about 5%), leading the authors to conclude that potential benefits might be outweighed by potential harms.

A meta-analysis breaking results down by compound found that THC-containing products drove most of the benefit. THC alone reduced pain intensity by about 8.7 points on a 100-point scale, and patients taking THC were roughly 1.9 times more likely to achieve a 30% pain reduction than those on placebo. CBD alone, by contrast, showed no significant pain-reducing effect.¹¹ Multiple randomized trials have found that the number of patients you need to treat for one to benefit is comparable to existing neuropathic pain drugs, though these trials have been limited by small sizes and short durations.¹²

The honest picture for pain: cannabis-based medicines produce a real but small average benefit for neuropathic pain, roughly in the same league as existing treatments. They are not the breakthrough that dispensary culture sometimes implies, and they come with side effects that conventional treatments may not. For people who have not responded to first-line therapies, though, they represent a reasonable option to try.

Cannabis, Anxiety, and PTSD

Mental health is where cannabis therapy gets complicated, because the same compounds that help some people feel calmer can make others feel worse. THC has dose-dependent effects on anxiety: animal studies suggest low doses reduce it while higher doses increase it. In human clinical studies, though, THC administration has mostly produced anxiety-increasing effects.¹³ There is an interesting disconnect between what people report in surveys (cannabis helps my anxiety) and what controlled experiments show (THC tends to increase anxiety in lab settings). That gap may reflect dosing differences, expectation effects, or the presence of other compounds like CBD in real-world products.

CBD, on the other hand, has shown fairly consistent anti-anxiety effects in both animal and human studies at acute doses, without triggering more anxiety at higher amounts.¹⁴ Animal research has suggested a bell-shaped dose-response curve, where low-to-moderate doses work but very high doses lose their effect.¹⁵ Both THC and CBD appear to affect mood and anxiety in a dose-dependent way, which means that the ratio and amount of each compound in a given product matters enormously.¹⁶

For PTSD specifically, early evidence points to cannabinoids helping with nightmares and sleep disturbances, two of the most treatment-resistant symptoms. A systematic review found that cannabinoids may reduce overall PTSD symptoms, with the strongest signal for sleep-related problems.¹⁷ A multicenter randomized trial of dronabinol (synthetic THC) for PTSD nightmares is underway, based on preliminary clinical data indicating that cannabinoid agonists can improve nightmares and overall PTSD symptoms.¹⁸ This is a case where the clinical signal looks promising but the well-controlled trials needed to confirm it are still in progress.

Sleep

Many cannabis users report better sleep, and there is some physiological basis for this: cannabis can increase slow-wave sleep (the deepest stage) and help people fall asleep faster.¹⁹ But the picture is more nuanced than “cannabis helps you sleep.” A pilot randomized trial using EEG monitoring found that a single dose of THC/CBD actually decreased total sleep time by about 25 minutes and substantially suppressed REM sleep, cutting it by roughly 34 minutes while delaying REM onset by over an hour.²⁰ REM sleep is important for memory consolidation and emotional processing, so suppressing it is not clearly a good thing, even if you subjectively feel like you slept better.

The benefits people report may also fade over time. Some studies show that improvements in sleep quality decline with chronic use, which aligns with what is known about tolerance.²¹ Research into cannabinoids for specific sleep disorders like insomnia, sleep apnea, and restless legs syndrome shows potential but remains limited by small sample sizes and study design issues.²² If you are using cannabis for sleep, the short version is: it probably changes your sleep architecture in ways you can feel subjectively, but whether those changes are genuinely restorative over the long term is unclear.

Cancer-Related Symptoms

Cannabis has a long association with cancer care, but mostly for symptom management rather than as a cancer treatment itself. Oral cannabinoids have shown similar or better results compared to older anti-nausea drugs for chemotherapy-induced nausea and vomiting.²³ This is one of the oldest medical uses of cannabinoids, and drugs like dronabinol and nabilone have been available for this purpose for decades.

The story is less encouraging for cancer-related weight loss and appetite. Despite the well-known “munchies” effect of THC, a systematic review with meta-analysis found no significant benefit of cannabinoids for appetite stimulation or weight gain in cancer cachexia compared to control groups. Patient reports sometimes described improved appetite, but the measured outcomes did not back that up.²⁴ The disconnect between subjective experience and objective measurement is a recurring theme in cannabis research.

Delivery Method Matters

How you take cannabis dramatically changes what your body actually absorbs. When inhaled, THC reaches peak blood levels within six to ten minutes and has a bioavailability of roughly 10% to 35%. When swallowed, bioavailability drops to about 4% to 12%, because the liver breaks down most of the THC before it reaches circulation. CBD follows a similar pattern: 11% to 45% bioavailability when inhaled, versus about 6% orally.²⁵ This has real consequences. An edible hits slower and lasts longer but delivers less of the active compound per milligram than inhalation. People who do not feel an edible’s effects quickly and take a second dose are a textbook source of emergency room visits.

Risks and Safety Concerns

Psychosis and Schizophrenia

Cannabis is a recognized risk factor for psychosis and schizophrenia, though the exact mechanism is not fully understood.²⁶ Brain imaging studies show that acute THC exposure produces patterns of disrupted brain activity that overlap with those seen in people experiencing a first episode of psychosis, particularly in the prefrontal cortex and limbic areas.²⁷ The relationship is not simple cause-and-effect; many people with similar neurobiological changes never develop schizophrenia. But for those with a genetic vulnerability, heavy cannabis use, particularly during adolescence, appears to lower the threshold for a psychotic episode. Cannabis users who do develop schizophrenia tend to have an earlier age of onset.²⁸

Drug Interactions

CBD in particular interacts with a surprisingly wide range of medications. Beyond the expected interactions with anti-epileptic drugs and opioid painkillers, CBD has been found to interact with antidepressants, common over-the-counter drugs like acetaminophen, and even alcohol and tobacco.²⁹ Most of these interactions occur because CBD affects the liver enzymes that metabolize other drugs, either speeding up or slowing down how quickly your body clears those medications. If you take prescription drugs and are considering CBD, this is a conversation to have with your prescriber.

Dependence and Withdrawal

THC is the primary driver of cannabis abuse potential. A subset of frequent users develops cannabis use disorder, which involves cravings, tolerance, and withdrawal symptoms that look a lot like other substance use disorders.³⁰ Withdrawal symptoms typically include irritability, sleep difficulty, reduced appetite, and anxiety. The risk is lower than with alcohol or opioids, but it is not zero, and the casual framing of cannabis as non-addictive does not hold up.

Older Adults

Cannabis therapy use among older adults has grown rapidly, and this population needs particular attention. In a study of patients over 65 who began medical cannabis (mostly for pain), about 58% were still using it six months later, and roughly 85% of those reported some improvement in their condition.³¹ About a third reported side effects, the most common being dizziness and sleepiness. A systematic review found that both THC and CBD had low rates of serious adverse events in older adults, though THC-CBD combinations carried a somewhat higher risk of withdrawal from treatment.³²

The caution with older adults centers on polypharmacy. Someone taking five or six medications has a much higher chance of hitting a drug interaction, and age-related changes in metabolism mean cannabinoids may stay active in the body longer. Fall risk from dizziness is also a real concern in this group. Careful, individualized dosing and frequent follow-up are the standard recommendation.

Prenatal Exposure

Cannabis use during pregnancy is a growing concern given rising legalization. A systematic review found that prenatal cannabis exposure does not appear to cause global developmental impairment, but it is associated with specific vulnerabilities. About 73% of studies examining behavioral regulation found negative associations, 69% found problems with attention, and 70% identified issues with executive functioning in exposed children. In contrast, most studies found no significant effects on overall cognition, language, or motor development after accounting for other factors.³³ Heavier or continued use after a mother becomes aware of the pregnancy showed stronger associations, suggesting dose-response and timing effects. A separate review found that exposed children consistently had higher ADHD risk and that higher THC concentrations were linked to more aggressive behavior in boys compared to girls.³⁴

Product Label Accuracy

If you are buying cannabis from a legal dispensary, you might assume the THC content on the label is accurate. Often it is not. A study testing 277 products found that only about 57% of flower products were accurately labeled within a 15% margin. Nearly a third of flower products were over-labeled, meaning they contained less THC than advertised, while about 13% were under-labeled. Concentrates fared much better, with 96% labeled accurately.³⁵ A separate analysis found a similar pattern: label values for flower and edible products were significantly higher than what testing actually measured.³⁶ For someone trying to follow a careful dosing protocol, inaccurate labeling makes that difficult and undermines the case for cannabis as a precisely dosed medicine.

Synthetic Cannabinoids Are a Different Story

Synthetic cannabinoids, sold under names like K2 and Spice, share the word “cannabinoid” with medical cannabis products but should be understood as fundamentally different drugs. They bind to the same receptors with much higher potency and can produce severe reactions including breathing difficulties, high blood pressure, rapid heart rate, kidney failure, psychosis, and suicidal thoughts.³⁷ They are more dangerous because they often contain unpredictable mixtures of highly potent compounds, and medical emergencies from synthetic cannabinoids are far more common and severe than from natural cannabis.³⁸ If someone describes a cannabis-related medical emergency, particularly involving seizures, severe agitation, or organ failure, synthetic cannabinoids should be suspected. They are not a therapeutic product by any measure.

Gut Health and Inflammatory Bowel Disease

Cannabis has drawn interest for inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, because cannabinoid receptors are densely distributed in the gut. A small but frequently cited trial of THC-rich cannabis in Crohn’s disease found that 10 of 11 patients in the cannabis group achieved a clinical response, compared to 4 of 10 in the placebo group. Patients also reported improved appetite and sleep without significant side effects, and three were able to stop taking steroids.³⁹ The catch: the study’s primary endpoint of achieving full remission was not met, and it remains unclear whether cannabinoids actually reduce the underlying intestinal inflammation or simply mask the symptoms of pain, nausea, and poor appetite.⁴⁰ That distinction is clinically important, because a patient who feels better while their intestinal disease silently progresses could end up in a worse situation.

Skin Conditions

Topical CBD has become a fixture in the skincare market, and some preclinical work supports its potential for conditions like eczema, psoriasis, and itching. CBD appears to have anti-inflammatory properties when applied to the skin, and early laboratory findings suggest it could be useful for certain inflammatory skin disorders.⁴¹ But “preclinical evidence suggests potential” is doing heavy lifting in a market generating billions of dollars. Confirmed clinical efficacy from rigorous human trials has not yet caught up with the commercial enthusiasm. The CBD face cream at your local pharmacy may or may not do anything, and the dose of CBD in cosmetic products is often far lower than what has been studied in any research context. If you are treating a diagnosed skin condition, evidence-based dermatological treatments remain the better-supported option for now.

1
PubMed Central. The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review ↩︎
2
PubMed Central. THC and CBD: Similarities and differences between siblings ↩︎
3
PubMed Central. The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders ↩︎
4
PubMed. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome ↩︎
5
PubMed. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results ↩︎
6
PubMed Central. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea ↩︎
7
PubMed. Sativex for the management of multiple sclerosis symptoms ↩︎
8
PubMed Central. The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms ↩︎
9
PubMed. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis ↩︎
10
PubMed Central. Cannabis‐based medicines for chronic neuropathic pain in adults ↩︎
11
PubMed Central. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis ↩︎
12
PubMed. Medical Cannabis for Neuropathic Pain ↩︎
13
PubMed Central. THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis’ primary cannabinoids ↩︎
14
PubMed Central. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties ↩︎
15
PubMed Central. THC, CBD, and Anxiety: A review of recent findings on the anxiolytic and anxiogenic effects of cannabis’ primary cannabinoids ↩︎
16
PubMed Central. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review ↩︎
17
PubMed. The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review ↩︎
18
PubMed Central. Treating nightmares in posttraumatic stress disorder with dronabinol: study protocol of a multicenter randomized controlled study (THC PTSD-trial) ↩︎
19
PubMed Central. The Effects of Cannabinoids on Sleep ↩︎
20
PubMed Central. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial ↩︎
21
PubMed Central. The Effects of Cannabinoids on Sleep ↩︎
22
PubMed Central. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders ↩︎
23
PubMed Central. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics ↩︎
24
PubMed Central. Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis ↩︎
25
PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis ↩︎
26
PubMed Central. Cannabis and psychosis: Neurobiology ↩︎
27
PubMed Central. Neurodevelopmental effects of perinatal exposure to cannabis on progeny: A narrative review – Section: THC and psychosis ↩︎
28
PubMed Central. Cannabis use and cognition in schizophrenia ↩︎
29
PubMed Central. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review ↩︎
30
PubMed Central. Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings ↩︎
31
PubMed Central. Medical Cannabis for Older Patients-Treatment Protocol and Initial Results ↩︎
32
PubMed. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies ↩︎
33
PubMed. Neurodevelopmental outcomes following prenatal cannabinoid exposure: a systematic review ↩︎
34
PubMed Central. Neurodevelopmental effects of perinatal exposure to cannabis on progeny: A narrative review ↩︎
35
PubMed Central. Accuracy of labeled THC potency across flower and concentrate cannabis products ↩︎
36
PLOS ONE. Commercial cannabis product testing: Fidelity to labels and regulations ↩︎
37
PubMed Central. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective ↩︎
38
PubMed. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions ↩︎
39
PubMed. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study ↩︎
40
PubMed Central. Therapeutic Use of Cannabis in Inflammatory Bowel Disease ↩︎
41
PubMed Central. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders ↩︎